Clinical trial · Observational
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With Multiple Myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
NCT06559033CI-TRIAL-00114237GAMYrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Monoclonal Gammopathy of Undetermined Significance | Monoclonal Gammopathy of Undetermined Significance | ONTOLOGY_EXACT | 0.98 |
| Myeloma Multiple | Multiple Myeloma | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Multiple myeloma (MM) patient group
- description
- patients with multiple myeloma (MM) (defined by a clonal proliferation of tumour plasma cells (\>10%), the presence of a monoclonal peak in the serum or urine (excluding non-secretory myeloma) and organ damage secondary to bone marrow invasion)
- interventionNames
- Biological: Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS
- label
- Monoclonal gammopathy of undetermined significance (MGUS) patient group
- description
- patients with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g/L and no clinical involvement)
- interventionNames
- Biological: Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS
- label
- Control group
- description
- patient with no pathology under study relating to the project
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (\>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g/L and no clinical involvement). * Membership of a social security scheme * Adult having read and understood the information letter and signed the consent form Exclusion Criteria: * Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship
References
Publications (0)
Data not yet available
No reference posted for this study.